Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 29, 2019 | Apr. 26, 2019 | |
Document and Entity Information [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Mar. 29, 2019 | |
Document Fiscal Year Focus | 2019 | |
Document Fiscal Period Focus | Q1 | |
Entity Registrant Name | EXPONENT INC | |
Entity Central Index Key | 0000851520 | |
Current Fiscal Year End Date | --01-03 | |
Entity Filer Category | Large Accelerated Filer | |
Trading Symbol | EXPO | |
Entity Common Stock, Shares Outstanding | 51,901,032 | |
Entity Emerging Growth Company | false | |
Entity Small Business | false |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 29, 2019 | Dec. 28, 2018 |
Current assets: | ||
Cash and cash equivalents | $ 79,080 | $ 127,059 |
Short-term investments | 92,680 | 81,495 |
Accounts receivable, net of allowance for contract losses and doubtful accounts of $4,713 and $4,066 at March 29, 2019 and December 28, 2018, respectively | 118,864 | 105,814 |
Prepaid expenses and other current assets | 13,986 | 12,244 |
Total current assets | 304,610 | 326,612 |
Property, equipment and leasehold improvements, net | 50,854 | 46,103 |
Operating lease right-of-use assets | 23,852 | 0 |
Goodwill | 8,607 | 8,607 |
Deferred income taxes | 33,878 | 34,090 |
Deferred compensation plan assets | 66,395 | 52,286 |
Other assets | 1,024 | 1,238 |
Total assets | 489,220 | 468,936 |
Current liabilities: | ||
Accounts payable and accrued liabilities | 12,377 | 12,283 |
Accrued payroll and employee benefits | 46,406 | 76,855 |
Deferred revenues | 7,567 | 9,166 |
Operating lease liabilities | 5,843 | 0 |
Total current liabilities | 72,193 | 98,304 |
Other liabilities | 2,702 | 2,548 |
Deferred compensation plan liabilities | 66,670 | 52,708 |
Deferred rent | 0 | 1,467 |
Operating lease liabilities | 18,478 | 0 |
Total liabilities | 160,043 | 155,027 |
Stockholders' equity: | ||
Common stock, $0.001 par value; 120,000 shares authorized; 65,707 shares issued at March 29, 2019 and December 28, 2018 | 66 | 66 |
Additional paid-in capital | 238,916 | 227,283 |
Accumulated other comprehensive income (loss) | ||
Investment securities, available-for-sale | 109 | (45) |
Foreign currency translation adjustments | (2,691) | (2,808) |
Accumulated other comprehensive income (loss) | (2,582) | (2,853) |
Retained earnings | 350,506 | 342,024 |
Treasury stock, at cost; 13,806 and 14,208 shares held at March 29, 2019 and December 28, 2018, respectively | (257,729) | (252,611) |
Total stockholders' equity | 329,177 | 313,909 |
Total liabilities and stockholders' equity | $ 489,220 | $ 468,936 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands | Mar. 29, 2019 | Dec. 28, 2018 |
Accounts receivable, net of allowance for contract losses and doubtful accounts | $ 4,713 | $ 4,066 |
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 120,000,000 | 120,000,000 |
Common stock, shares issued | 65,707,000 | 65,707,000 |
Treasury stock, shares | 13,806,000 | 14,208,000 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
Mar. 29, 2019 | Mar. 30, 2018 | |
Revenues: | ||
Revenues before reimbursements | $ 93,401 | $ 90,684 |
Reimbursements | 5,630 | 5,773 |
Revenues | 99,031 | 96,457 |
Operating expenses: | ||
Compensation and related expenses | 65,093 | 57,579 |
Other operating expenses | 8,008 | 7,465 |
Reimbursable expenses | 5,630 | 5,773 |
General and administrative expenses | 4,546 | 4,042 |
Total operating expenses | 83,277 | 74,859 |
Operating income | 15,754 | 21,598 |
Other income, net: | ||
Interest income, net | 1,055 | 530 |
Miscellaneous income, net | 6,513 | 322 |
Total other income, net | 7,568 | 852 |
Income before income taxes | 23,322 | 22,450 |
Income taxes | 610 | 2,110 |
Net income | $ 22,712 | $ 20,340 |
Net income per share: | ||
Basic (in dollars per share) | $ 0.43 | $ 0.39 |
Diluted (in dollars per share) | $ 0.42 | $ 0.38 |
Shares used in per share computations: | ||
Basic (in shares) | 52,536 | 52,744 |
Diluted (in shares) | 53,814 | 54,012 |
Cash dividends declared per common share (in dollars per share) | $ 0.16 | $ 0.13 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 29, 2019 | Mar. 30, 2018 | |
Net income | $ 22,712 | $ 20,340 |
Other comprehensive income (loss): | ||
Foreign currency translation adjustments, net of tax | 117 | 739 |
Unrealized gains (losses) on available-for-sale investment securities arising during the period, net of tax | 154 | (40) |
Comprehensive income | $ 22,983 | $ 21,039 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands | Total | Common Stock [Member] | Additional paid-in capital [Member] | Accumulated other comprehensive income (loss) [Member] | Retained earnings [Member] | Treasury Stock [Member] |
Balance at Dec. 29, 2017 | $ 289,088 | $ 66 | $ 210,230 | $ (2,029) | $ 303,990 | $ (223,169) |
Balances (in shares) at Dec. 29, 2017 | 65,707 | 14,169 | ||||
Employee stock purchase plan | 310 | $ 0 | 230 | 0 | 0 | $ 80 |
Employee stock purchase plan (in shares) | (8) | |||||
Amortization of unrecognized stock-based compensation | 4,057 | 0 | 4,057 | 0 | 0 | $ 0 |
Foreign currency translation adjustments | 739 | 0 | 0 | 739 | 0 | 0 |
Grant of restricted stock units to settle accrued bonus | 7,643 | 0 | 7,643 | 0 | 0 | 0 |
Settlement of restricted stock units | (8,637) | 0 | (806) | 0 | (5,892) | $ (1,939) |
Settlement of restricted stock units (in shares) | (463) | |||||
Unrealized loss on investments | (40) | 0 | 0 | (40) | 0 | $ 0 |
Dividends and dividend equivalent rights | (6,875) | 0 | 585 | 0 | (7,460) | 0 |
Net income | 20,340 | 0 | 0 | 0 | 20,340 | 0 |
Balance at Mar. 30, 2018 | 306,625 | $ 66 | 221,939 | (1,330) | 310,978 | $ (225,028) |
Balances (in shares) at Mar. 30, 2018 | 65,707 | 13,698 | ||||
Balance at Dec. 28, 2018 | 313,909 | $ 66 | 227,283 | (2,853) | 342,024 | $ (252,611) |
Balances (in shares) at Dec. 28, 2018 | 65,707 | 14,208 | ||||
Employee stock purchase plan | 372 | $ 0 | 302 | 0 | 0 | $ 70 |
Employee stock purchase plan (in shares) | (7) | |||||
Amortization of unrecognized stock-based compensation | 3,663 | 0 | 3,663 | 0 | 0 | $ 0 |
Foreign currency translation adjustments | 117 | 0 | 0 | 117 | 0 | 0 |
Grant of restricted stock units to settle accrued bonus | 7,947 | 0 | 7,947 | 0 | 0 | 0 |
Settlement of restricted stock units | (11,194) | 0 | (860) | 0 | (5,146) | $ (5,188) |
Settlement of restricted stock units (in shares) | (395) | |||||
Unrealized loss on investments | 154 | 0 | 0 | 154 | 0 | $ 0 |
Dividends and dividend equivalent rights | (8,503) | 0 | 581 | 0 | (9,084) | 0 |
Net income | 22,712 | 0 | 0 | 0 | 22,712 | 0 |
Balance at Mar. 29, 2019 | $ 329,177 | $ 66 | $ 238,916 | $ (2,582) | $ 350,506 | $ (257,729) |
Balances (in shares) at Mar. 29, 2019 | 65,707 | 13,806 |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 29, 2019 | Mar. 30, 2018 | |
Cash flows from operating activities: | ||
Net income | $ 22,712 | $ 20,340 |
Adjustments to reconcile net income to net cash provided by (used in) operating activities: | ||
Depreciation and amortization of property, equipment and leasehold improvements | 1,590 | 1,555 |
Amortization of premiums and accretion of discounts on short-term investments | (132) | 0 |
Deferred rent | 0 | (74) |
Provision for contract losses and doubtful accounts | 788 | 561 |
Stock-based compensation | 5,731 | 6,289 |
Deferred income tax provision | 161 | (815) |
Changes in operating assets and liabilities: | ||
Accounts receivable | (13,838) | (7,700) |
Prepaid expenses and other current assets | (10,431) | (5,520) |
Change in operating leases | (425) | 0 |
Accounts payable and accrued liabilities | (333) | 1,829 |
Accrued payroll and employee benefits | (16,477) | (12,383) |
Deferred revenues | (1,599) | (390) |
Net cash (used in) provided by operating activities | (12,253) | 3,692 |
Cash flows from investing activities: | ||
Capital expenditures | (5,670) | (6,810) |
Purchase of short-term investments | (23,848) | (11,934) |
Maturity of short-term investments | 13,000 | 8,000 |
Net cash used in investing activities | (16,518) | (10,744) |
Cash flows from financing activities: | ||
Payroll taxes for restricted stock units | (11,194) | (8,637) |
Exercise of stock-based payment awards | 372 | 310 |
Dividends and dividend equivalents rights | (8,593) | (6,959) |
Net cash used in financing activities | (19,415) | (15,286) |
Effect of foreign currency exchange rates on cash and cash equivalents | 207 | 696 |
Net decrease in cash and cash equivalents | (47,979) | (21,642) |
Cash and cash equivalents at beginning of period | 127,059 | 124,794 |
Cash and cash equivalents at end of period | $ 79,080 | $ 103,152 |
Basis of Presentation
Basis of Presentation | 3 Months Ended |
Mar. 29, 2019 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Basis of Presentation | Note 1: Basis of Presentation Exponent, Inc. (referred to as the “Company” or “Exponent”) is an engineering and scientific consulting firm that provides solutions to complex problems. The Company operates on a 52-53 week fiscal year ending on the Friday closest to the last day of December. The accompanying unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission. Accordingly, they do not contain all the information and notes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments which are necessary for the fair presentation of the condensed consolidated financial statements have been included and all such adjustments are of a normal and recurring nature. The operating results for the three months ended March 29, 2019 are not necessarily representative of the results of future quarterly or annual periods. The following information should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 28, 2018, which was filed with the U.S. Securities and Exchange Commission on February 22, 2019. The unaudited condensed consolidated financial statements include the accounts of Exponent, Inc. and its subsidiaries, which are all wholly owned. All intercompany accounts and transactions have been eliminated in consolidation. Stock Split. On May 31, 2018, the Company’s stockholders approved an amendment to the Company’s certificate of incorporation to (i) increase the number of authorized shares of common stock to 120,000,000 and (ii) effect a two-for-one stock split. As a result of the stock split, each shareholder of record at the close of business on May 31, 2018, received one additional share of common stock for each share of common stock owned by such shareholder. Restricted stock unit awards and stock option awards have also been adjusted to reflect the two-for-one stock split. For periods prior to the stock split, all share and per share data in the Company’s condensed consolidated financial statements and related notes have been retroactively adjusted to reflect the stock split. Dividend. The Company declared and paid cash dividends per common share during the periods presented as follows: Fiscal Year 2019 Dividends Amount Per Share (in thousands) First Quarter $ 0.16 $ 8,240 Total $ 0.16 $ 8,240 Fiscal Year 2018 Dividends Amount Per Share (in thousands) First Quarter $ 0.13 $ 6,700 Second Quarter 0.13 6,764 Third Quarter 0.13 6,765 Fourth Quarter 0.13 6,723 Total $ 0.52 $ 26,952 On April 18, 2019, the Company’s Board of Directors announced a cash dividend of $0.16 per share of the Company’s common stock, payable June 21, 2019 to stockholders of record as of June 7, 2019. The Company expects to continue paying quarterly dividends in the future, subject to declaration by the Company’s Board of Directors. Use of Estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Items subject to such estimates and assumptions include accounting for revenue recognition and estimating the allowance for contract losses and doubtful accounts. Actual results could differ from those estimates. Recently Adopted Accounting Pronouncements. The Company adopted the ASU as of the beginning of its first quarter of fiscal 2019. A modified retrospective transition approach is required, requiring the application of the new standard to all leases existing at the date of initial application. An entity may choose to use either (1) its effective date or (2) the beginning of the earliest comparative period presented in the financial statements as its date of initial application. The Company adopted the new standard on December 29, 2018 using the effective date as the date of initial application. Consequently, financial information was not updated and the disclosures required under the new standard were not provided for dates and periods before December 29, 2018. The new standard provides a number of optional practical expedients in transition. The Company elected the ‘package of practical expedients’, which permits it not to reassess under the new standard prior conclusions about lease identification, lease classification and initial direct costs. The Company elected the practical expedient to include both lease and non-lease components as a single component and account for it as a lease for all asset classes. The Company also elected to apply the short-term lease exception for all leases. Under the short-term lease exception, the Company will not recognize ROU assets or lease liabilities for leases that, at the acquisition date, have a remaining lease term of 12 months or less. The ASU had a material impact to the Company’s condensed consolidated balance sheet, but did not have an impact on its condensed consolidated statement of income. The most significant impact was the recognition of ROU assets and lease liabilities for its operating leases. |
Revenue Recognition
Revenue Recognition | 3 Months Ended |
Mar. 29, 2019 | |
Revenue Recognition [Abstract] | |
Revenue Recognition | Note 2: Revenue Recognition Substantially all of the Company’s engagements are performed under time and materials or fixed-price arrangements. For time and materials contracts, the Company utilizes the practical expedient under Accounting Standards Codification 606 – Revenue from Contracts with Customers, which states, if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity’s performance completed to date (for example, a service contract in which an entity bills a fixed amount for each hour of service provided), the entity may recognize revenue in the amount to which the entity has a right to invoice. During the first quarter of fiscal 2019, the Company recognized revenue of $83,397,000 associated with time and materials contracts. These revenues represent 84% of the Company’s consolidated revenues and include revenues of $65,379,000 for the Company’s Engineering and Other Scientific segment and $18,018,000 for the Company’s Environmental and Health segment. During the first quarter of fiscal 2018, the Company recognized revenue of $83,171,000 associated with time and materials contracts. These revenues represent 86% of the Company’s consolidated revenues and include revenues of $64,557,000 for the Company’s Engineering and Other Scientific segment and $18,614,000 for the Company’s Environmental and Health segment. The Company’s time and materials contracts are terminable and subject to postponement or delay at any time by our clients, and as such, the performance obligations for all of the Company’s time and materials contracts have an original expected duration of one year or less. For fixed-price contracts the Company recognizes revenue over time because of the continuous transfer of control to the customer. The customer typically controls the work in process as evidenced either by contractual termination clauses or by the Company’s rights to payment for work performed to date to deliver services that do not have an alternative use to the Company. Revenue for fixed-price contracts is recognized based on the relationship of incurred labor hours at standard rates to the Company’s estimate of the total labor hours at standard rates it expects to incur over the term of the contract. The Company believes this methodology achieves a reliable measure of the revenue from the consulting services it provides to its customers under fixed-price contracts given the nature of the consulting services the Company provides and the following additional considerations: the Company considers labor hours at standard rates and expenses to be incurred when pricing its contracts; the Company generally does not incur set up costs on its contracts; the Company does not believe that there are reliable milestones to measure progress towards completion; the customer is required to pay the Company for time at standard rates plus materials incurred to date if the contract is terminated early; the Company’s contracts do not include award fees or bonuses; the Company does not include revenue for unpriced change orders until the customer agrees with the changes; historically the Company has not had significant accounts receivable write-offs or cost overruns; and the Company’s contracts are typically progress billed on a monthly basis. During the first quarter of fiscal 2019 the Company recognized revenue of $15,634,000 associated with fixed-price contracts. These revenues represent 16% of the Company’s consolidated revenues and include revenues of $14,875,000 for the Company’s Engineering and Other Scientific segment and $759,000 for the Company’s Environmental and Health segment. During the first quarter of fiscal 2018 the Company recognized revenue of $13,286,000 associated with fixed-price contracts. These revenues represent 14% of the Company’s consolidated revenues and include revenues of $12,446,000 for the Company’s Engineering and Other Scientific segment and $840,000 for the Company’s Environmental and Health segment. The Company’s fixed-price contracts are terminable and subject to postponement or delay at any time by our clients, and as such, the performance obligations for all of the Company’s fixed-price contracts have an original expected duration of one year or less. Deferred revenues represent amounts billed to clients in advance of services provided. During the first quarter of fiscal 2019, $3,411,000 of revenues were recognized that were included in the deferred revenue balance at December 28, 2018. Reimbursements, including those related to travel and other out-of-pocket expenses, and other similar third party costs such as the cost of materials and certain subcontracts, are included in revenues, and an equivalent amount of reimbursable expenses are included in operating expenses. Any mark-up on reimbursable expenses is included in revenues before reimbursements. The Company reports revenues net of subcontractor fees for certain subcontracts where the Company has determined that it is acting as an agent because its performance obligation is to arrange for the provision of goods or services by another party. The total amount of subcontractor fees not included in revenues because the Company was acting as an agent were $4.2 million during the first quarter of fiscal 2019. The total amount of subcontractor fees not included in revenues because the Company was acting as an agent were $10.2 million during the first quarter of fiscal 2018. |
Fair Value Measurements
Fair Value Measurements | 3 Months Ended |
Mar. 29, 2019 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Note 3: Fair Value Measurements The Company measures certain financial assets and liabilities at fair value on a recurring basis, including available-for-sale fixed income securities, trading fixed income and equity securities held in its deferred compensation plan and the liability associated with its deferred compensation plan. There were no transfers between fair value measurement levels during the three months ended March 29, 2019 and March 30, 2018. Any transfers between fair value measurement levels would be recorded on the actual date of the event or change in circumstances that caused the transfer. The fair value of these certain financial assets and liabilities was determined using the following inputs at March 29, 2019: Fair Value Measurements at Reporting Date Using (In thousands) Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Money market securities (1) $ 770 $ 770 $ - $ - Fixed income available-for-sale securities (2) 92,680 - 92,680 - Fixed income trading securities held in deferred compensation plan (3) 25,504 25,504 - - Equity trading securities held in deferred compensation plan (3) 46,240 46,240 - - Total $ 165,194 $ 72,514 $ 92,680 $ - Liabilities Deferred compensation plan (4) 73,119 73,119 - - Total $ 73,119 $ 73,119 $ - $ - (1) Included in cash and cash equivalents on the Company’s unaudited condensed consolidated balance sheet. (2) Included in short-term investments on the Company’s unaudited condensed consolidated balance sheet. (3) Included in prepaid expenses and other current assets and deferred compensation plan assets on the Company’s unaudited condensed consolidated balance sheet. (4) Included in accrued payroll and employee benefits and deferred compensation plan liabilities on the Company’s unaudited condensed consolidated balance sheet. The fair value of these certain financial assets and liabilities was determined using the following inputs at December 28, 2018: Fair Value Measurements at Reporting Date Using Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Money market securities (1) $ 6,213 $ 6,213 $ - $ - Fixed income available for sale securities (2) 81,495 - 81,495 - Fixed income trading securities held in deferred compensation plan (3) 18,618 18,618 - - Equity trading securities held in deferred compensation plan (3) 39,160 39,160 - - Total $ 145,486 $ 63,991 $ 81,495 $ - Liabilities Deferred compensation plan (4) 59,349 59,349 - - Total $ 59,349 $ 59,349 $ - $ - (1) Included in cash and cash equivalents on the Company’s unaudited condensed consolidated balance sheet. (2) Included in short-term investments on the Company’s unaudited condensed consolidated balance sheet. (3) (4) Included in accrued payroll and employee benefits and deferred compensation plan liabilities on the Company’s unaudited condensed consolidated balance sheet. Fixed income available-for-sale securities as of March 29, 2019 and December 28, 2018 represent obligations of the United States Treasury and other United States agencies. Fixed income and equity trading securities represent mutual funds held in the Company’s deferred compensation plan. See Note 7 for additional information about the Company’s deferred compensation plan. Cash, cash equivalents and short-term investments consisted of the following as of March 29, 2019: Gross Gross Amortized Unrealized Unrealized Estimated (In thousands) Cost Gains Losses Fair Value Classified as current assets: Cash $ 73,310 $ - $ - $ 73,310 Cash equivalents: Money market securities 770 - - 770 U.S. Treasury securities 5,000 - - 5,000 Total cash equivalents 5,770 - - 5,770 Total cash and cash equivalents 79,080 - - 79,080 Short-term investments: U.S. Treasury and agency securities 92,613 174 (107 ) 92,680 Total short-term investments 92,613 174 (107 ) 92,680 Total cash, cash equivalents and short-term investments $ 171,693 $ 174 $ (107 ) $ 171,760 Cash, cash equivalents and short-term investments consisted of the following as of December 28, 2018: Amortized Unrealized Unrealized Estimated (In thousands) Cost Gains Losses Fair Value Classified as current assets: Cash $ 120,846 $ - $ - $ 120,846 Cash equivalents: Money market securities 6,213 - - 6,213 Total cash equivalents 6,213 - - 6,213 Total cash and cash equivalents 127,059 - - 127,059 Short-term investments: U.S. Treasury and agency securities 81,634 91 (230 ) 81,495 Total short-term investments 81,634 91 (230 ) 81,495 Total cash, cash equivalents and short-term investments $ 208,693 $ 91 $ (230 ) $ 208,554 The following table summarizes the cost and estimated fair value of short-term fixed income securities classified as short-term investments based on stated effective maturities as of March 29, 2019: Amortized Estimated (In thousands) Cost Fair Value Due within one year $ 46,919 $ 46,815 Due between one and two years 45,694 45,865 Total $ 92,613 $ 92,680 At March 29, 2019 and December 28, 2018, the Company did not have any assets or liabilities valued using significant unobservable inputs. The following financial instruments are not measured at fair value on the Company's unaudited condensed consolidated balance sheet at March 29, 2019 and December 28, 2018, but require disclosure of their fair values: accounts receivable, other assets and accounts payable. The estimated fair value of such instruments at March 29, 2019 and December 28, 2018 approximates their carrying value as reported on the Company’s unaudited condensed consolidated balance sheet. There were no other-than-temporary impairments or credit losses related to available-for-sale securities during the three months ended March 29, 2019 and March 30, 2018. |
Net Income Per Share
Net Income Per Share | 3 Months Ended |
Mar. 29, 2019 | |
Earnings Per Share [Abstract] | |
Net Income Per Share | Note 4: Net Income Per Share Basic per share amounts are computed using the weighted-average number of common shares outstanding during the period. Diluted per share amounts are calculated using the weighted-average number of common shares outstanding during the period and, when dilutive, the weighted-average number of potential common shares from the issuance of common stock to satisfy outstanding restricted stock units and the exercise of outstanding options to purchase common stock using the treasury stock method. The following schedule reconciles the shares used to calculate basic and diluted net income per share: Three Months Ended (In thousands) March 29, 2019 March 30, 2018 Shares used in basic per share computation 52,536 52,744 Effect of dilutive common stock options outstanding 455 322 Effect of dilutive restricted stock units outstanding 823 946 Shares used in diluted per share computation 53,814 54,012 Common stock options to purchase 24,176 shares were excluded from the diluted per share calculation for the three months ended March 29, 2019 due to their antidilutive effect. The weighted-average exercise price for the antidilutive shares was $54.95 for the three months ended March 29, 2019. There were no options excluded from the diluted per share calculations for the three months ended March 30, 2018. |
Stock-Based Compensation
Stock-Based Compensation | 3 Months Ended |
Mar. 29, 2019 | |
Share-based Compensation [Abstract] | |
Stock-Based Compensation | Note 5: Stock-Based Compensation Restricted Stock Units Restricted stock unit grants are designed to attract and retain employees, and to better align employee interests with those of the Company’s stockholders. For a select group of employees, up to 40% of their annual bonus is settled with fully vested restricted stock unit awards. Under these fully vested restricted stock unit awards, the holder of each award has the right to receive one share of the Company’s common stock for each fully vested restricted stock unit four years from the date of grant. Each individual who receives a fully vested restricted stock unit award is also granted a matching number of unvested restricted stock unit awards. Unvested restricted stock unit awards are also granted for select new hires and promotions. These unvested restricted stock unit awards generally cliff vest four years from the date of grant, at which time the holder of each award will have the right to receive one share of the Company’s common stock for each restricted stock unit award provided the holder of each award has met certain employment conditions. In the case of retirement at 59½ years or older, all unvested restricted stock unit awards will continue to vest, provided that the holder of each award does all consulting work through the Company and does not become an employee for a past or present client, beneficial party or competitor of the Company. The value of these restricted stock unit awards is determined based on the market price of the Company’s common stock on the date of grant. The value of fully vested restricted stock unit awards issued is recorded as a reduction to accrued bonuses. The portion of bonus expense that the Company expects to settle with fully vested restricted stock unit awards is recorded as stock-based compensation during the period the bonus is earned. The Company recorded stock-based compensation expense associated with accrued bonus awards of $2,068,000 and $2,232,000 during the three months ended March 29, 2019 and March 30, 2018, respectively. The value of the unvested restricted stock unit awards granted is recognized on a straight-line basis over the shorter of the four-year vesting period or the period between the grant date and the date the award recipient turns 59½. If the award recipient is 59½ years or older on the date of grant, the value of the entire award is expensed upon grant. The Company recorded stock-based compensation expense associated with the unvested restricted stock unit awards of $3,530,000 and $3,508,000 during the three months ended March 29, 2019 and March 30, 2018, respectively. Stock Options Stock options are granted for terms of ten years and generally vest 25% per year over a four-year period from the grant date. Unvested stock option awards will continue to vest in the case of retirement at 59½ years or older, provided that the holder of each award does all consulting work through the Company and does not become an employee for a past or present client, beneficial party or competitor of the Company. The value of the unvested stock option awards granted is recognized on a straight-line basis over the shorter of the four-year vesting period or the period between the grant date and the date the award recipient turns 59½. If the award recipient is 59½ years or older on the date of grant, the value of the entire award is expensed upon grant. The Company grants options at exercise prices equal to the fair value of the Company’s common stock on the date of grant. The Company recorded stock-based compensation expense associated with stock option grants of $133,000 and $549,000 during the three months ended March 29, 2019 and March 30, 2018, respectively. The Company uses the Black-Scholes option-pricing model to determine the fair value of options granted. The determination of the fair value of stock option awards on the date of grant using an option-pricing model is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables. These variables include expected stock price volatility over the term of the award, actual and projected employee stock option exercise behaviors, the risk-free interest rate and expected dividends. The Company used historical exercise, forfeiture, and post-vesting expiration data to estimate the expected term of options granted. The historical volatility of the Company’s common stock over a period of time equal to the expected term of the options granted was used to estimate expected volatility. The risk-free interest rate used in the option-pricing model was based on United States Treasury zero-coupon issues with remaining terms similar to the expected term of the options. The dividend yield assumption considers the expectation of continued declaration of dividends, offset by option holders’ dividend equivalent rights. The Company accounts for forfeitures of stock-based awards when they occur. All stock-based payment awards are recognized on a straight-line basis over the requisite service periods of the awards. |
Treasury Stock
Treasury Stock | 3 Months Ended |
Mar. 29, 2019 | |
Equity [Abstract] | |
Treasury Stock | Note 6: Treasury Stock On October 19, 2016, the Company’s Board of Directors $35,000,000 for the repurchase of shares of the Company’s common stock. On January 31, 2019, the Company’s Board of Directors an additional $75,000,000 for the repurchase of shares of the Company’s common stock. The Company did not repurchase any shares of its common stock during the three months ended March 29, 2019 and March 30, 2018. As of March 29, 2019, the Company had remaining authorization under its stock repurchase plans of $92,462,000 to repurchase shares of common stock. |
Deferred Compensation Plans
Deferred Compensation Plans | 3 Months Ended |
Mar. 29, 2019 | |
Deferred Compensation Arrangements [Abstract] | |
Deferred Compensation Plans | Note 7: Deferred Compensation Plans The Company maintains nonqualified deferred compensation plans for the benefit of a select group of highly compensated employees. Under these plans, participants may elect to defer up to 100% of their compensation. Company assets that are earmarked to pay benefits under the plans are held in a rabbi trust and are subject to the claims of the Company’s creditors. As of March 29, 2019 and December 28, 2018, the invested amounts under the plans totaled $71,744,000 and $57,778,000, As of March 29, 2019 and December 28, 2018, vested amounts due under the plans totaled $73,119,000 and $59,349,000, respectively, and are recorded within accrued payroll and employee benefits and deferred compensation |
Supplemental Cash Flow Informat
Supplemental Cash Flow Information | 3 Months Ended |
Mar. 29, 2019 | |
Supplemental Cash Flow Information [Abstract] | |
Supplemental Cash Flow Information | Note 8: Supplemental Cash Flow Information The following is supplemental disclosure of cash flow information: Three Months Ended (In thousands) March 29, 2019 March 30, 2018 Cash paid during period: Income taxes $ 440 $ 678 Non-cash investing and financing activities: Unrealized gain (loss) on short-term investments $ 154 $ (40 ) Vested stock unit awards issued to settle accrued bonuses $ 7,947 $ 7,643 Accrual for capital expenditures $ 1,903 $ 299 Right-of-use asset obtained in exchange for operating lease obligations $ 25,653 $ - |
Accounts Receivable, Net
Accounts Receivable, Net | 3 Months Ended |
Mar. 29, 2019 | |
Receivables [Abstract] | |
Accounts Receivable, Net | Note 9: Accounts Receivable, Net At March 29, 2019 and December 28, 2018, accounts receivable, net, was comprised of the following: March 29, December 28, (In thousands) 2019 2018 Billed accounts receivable $ 78,814 $ 73,905 Unbilled accounts receivable 44,763 35,975 Allowance for contract losses and doubtful accounts (4,713 ) (4,066 ) Total accounts receivable, net $ 118,864 $ 105,814 On January 29 th |
Segment Reporting
Segment Reporting | 3 Months Ended |
Mar. 29, 2019 | |
Segment Reporting [Abstract] | |
Segment Reporting | Note 10: Segment Reporting The Company has two reportable operating segments based on two primary areas of service. The Engineering and Other Scientific segment is a broad service group providing technical consulting in different practices primarily in engineering. The Environmental and Health segment provides services in the area of environmental, epidemiology and health risk analysis. This segment provides a wide range of consulting services relating to environmental hazards and risks and the impact on both human health and the environment. Our Chief Executive Officer, the chief operating decision maker, reviews revenues and operating income for each of our reportable segments but does not review total assets in evaluating segment performance and capital allocation. Segment information for the three months ended March 29, 2019 and March 30, 2018 follows: Revenues Three Months Ended (In thousands) March 29, 2019 March 30, 2018 Engineering and Other Scientific $ 80,254 $ 77,047 Environmental and Health 18,777 19,410 Total revenues $ 99,031 $ 96,457 Operating Income Three Months Ended (In thousands) March 29, 2019 March 30, 2018 Engineering and Other Scientific $ 25,974 $ 25,913 Environmental and Health 6,196 6,624 Total segment operating income 32,170 32,537 Corporate operating expense (16,416 ) (10,939 ) Total operating income $ 15,754 $ 21,598 Capital Expenditures Three Months Ended (In thousands) March 29, 2019 March 30, 2018 Engineering and Other Scientific $ 1,778 $ 813 Environmental and Health 43 51 Total segment capital expenditures 1,821 864 Corporate capital expenditures 4,520 5,946 Total capital expenditures $ 6,341 $ 6,810 Depreciation and Amortization Three Months Ended (In thousands) March 29, 2019 March 30, 2018 Engineering and Other Scientific $ 1,121 $ 1,095 Environmental and Health 45 39 Total segment depreciation and amortization 1,166 1,134 Corporate depreciation and amortization 424 421 Total depreciation and amortization $ 1,590 $ 1,555 No single client comprised more than 10% of the Company’s revenues during the three months ended March 29, 2019. One client comprised 16% of the Company’s revenues during the three months ended March 30, 2018. No other single client comprised more than 10% of the Company’s revenues during the three months ended March 30, 2018. One client comprised 13% of the Company’s accounts receivable at March 29, 2019. No single client comprised more than 10% of the Company’s accounts receivable at December 28, 2018. |
Leases
Leases | 3 Months Ended |
Mar. 29, 2019 | |
Leases [Abstract] | |
Leases of Lessee Disclosure [Text Block] | Note 11: Leases The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities, and long-term operating lease liabilities in the Company’s condensed consolidated balance sheet. The Company does not have any finance leases as of March 29, 2019. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate, based on the information available at commencement date, in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The amortization of operating lease ROU assets and the change in operating lease liabilities is disclosed as a single line item in the condensed consolidated statement of cash flows. The Company leases office, laboratory, and storage space in 13 states and the District of Columbia, as well as in Germany, China, Hong Kong, Singapore, Switzerland and the United Kingdom. Leases for these office, laboratory, and storage facilities have terms generally ranging between one and ten years. Some of these leases include options to extend or terminate the lease, none of which are currently included in the lease term as the Company has determined that exercise of these options is not reasonably certain. The Company has a Test and Engineering Center on 147 acres of land in Phoenix, Arizona. The Company leases this land from the state of Arizona under a 30-year lease agreement that expires in January of 2028 and has options to renew for two fifteen-year periods. As of March 29, 2019, the Company has determined that exercise of the renewal options is not reasonably certain and thus the extension is not included in the lease term. The Company’s equipment leases are included in the ROU asset and liability balances but are not material. The Company leases excess space in its Silicon Valley facility. Rental income of $741,000 was included in other income for the three months ended March 29, 2019. The components of lease expense included in other operating expenses on the condensed consolidated statement of income were as follows: (In thousands) Three Months Ended March 29, 2019 Operating lease cost $ 1,870 Variable lease cost $ 380 Short-term lease cost $ 95 Supplemental cash flow information related to operating leases was as follows: (In thousands) Three Months Ended March 29, 2019 Cash paid for amounts included in the measurement of lease liabilities: $ 2,534 Supplemental balance sheet information related to operating leases was as follows: Three Months Ended March 29, 2019 Weighted Average Remaining Lease Term 5.6 years Weighted Average Discount Rate 4.5 % Maturities of operating lease liabilities as of March 29, 2019: Operating (In thousands) Leases 2019 (excluding three months ended March 29, 2019) $ 4,700 2020 6,001 2021 4,950 2022 3,894 2023 2,601 2024 1,693 2025 1,491 2026 1,507 2027 1,466 Total lease payments $ 28,303 Less imputed interest (3,982 ) Total lease liability $ 24,321 |
Contingencies
Contingencies | 3 Months Ended |
Mar. 29, 2019 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Note 12: Contingencies The Company is a party to various legal actions from time to time and may be contingently liable in connection with claims and contracts arising in the normal course of business, the outcome of which the Company believes, after consultation with legal counsel, will not have a material adverse effect on its financial condition, results of operations or liquidity. However, due to the risks and uncertainties inherent in legal proceedings, actual results could differ from current expected results. All legal costs associated with litigation are expensed as incurred. |
Basis of Presentation (Policies
Basis of Presentation (Policies) | 3 Months Ended |
Mar. 29, 2019 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation Exponent, Inc. (referred to as the “Company” or “Exponent”) is an engineering and scientific consulting firm that provides solutions to complex problems. The Company operates on a 52-53 week fiscal year ending on the Friday closest to the last day of December. The accompanying unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission. Accordingly, they do not contain all the information and notes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments which are necessary for the fair presentation of the condensed consolidated financial statements have been included and all such adjustments are of a normal and recurring nature. The operating results for the three months ended March 29, 2019 are not necessarily representative of the results of future quarterly or annual periods. The following information should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 28, 2018, which was filed with the U.S. Securities and Exchange Commission on February 22, 2019. The unaudited condensed consolidated financial statements include the accounts of Exponent, Inc. and its subsidiaries, which are all wholly owned. All intercompany accounts and transactions have been eliminated in consolidation. |
Stock Split | Stock Split. On May 31, 2018, the Company’s stockholders approved an amendment to the Company’s certificate of incorporation to (i) increase the number of authorized shares of common stock to 120,000,000 and (ii) effect a two-for-one stock split. As a result of the stock split, each shareholder of record at the close of business on May 31, 2018, received one additional share of common stock for each share of common stock owned by such shareholder. Restricted stock unit awards and stock option awards have also been adjusted to reflect the two-for-one stock split. For periods prior to the stock split, all share and per share data in the Company’s condensed consolidated financial statements and related notes have been retroactively adjusted to reflect the stock split. |
Dividend | Dividend. The Company declared and paid cash dividends per common share during the periods presented as follows: Fiscal Year 2019 Dividends Amount Per Share (in thousands) First Quarter $ 0.16 $ 8,240 Total $ 0.16 $ 8,240 Fiscal Year 2018 Dividends Amount Per Share (in thousands) First Quarter $ 0.13 $ 6,700 Second Quarter 0.13 6,764 Third Quarter 0.13 6,765 Fourth Quarter 0.13 6,723 Total $ 0.52 $ 26,952 On April 18, 2019, the Company’s Board of Directors announced a cash dividend of $0.16 per share of the Company’s common stock, payable June 21, 2019 to stockholders of record as of June 7, 2019. The Company expects to continue paying quarterly dividends in the future, subject to declaration by the Company’s Board of Directors. |
Use of Estimates | Use of Estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Items subject to such estimates and assumptions include accounting for revenue recognition and estimating the allowance for contract losses and doubtful accounts. Actual results could differ from those estimates. |
Recently Adopted Accounting Pronouncements | Recently Adopted Accounting Pronouncements. The Company adopted the ASU as of the beginning of its first quarter of fiscal 2019. A modified retrospective transition approach is required, requiring the application of the new standard to all leases existing at the date of initial application. An entity may choose to use either (1) its effective date or (2) the beginning of the earliest comparative period presented in the financial statements as its date of initial application. The Company adopted the new standard on December 29, 2018 using the effective date as the date of initial application. Consequently, financial information was not updated and the disclosures required under the new standard were not provided for dates and periods before December 29, 2018. The new standard provides a number of optional practical expedients in transition. The Company elected the ‘package of practical expedients’, which permits it not to reassess under the new standard prior conclusions about lease identification, lease classification and initial direct costs. The Company elected the practical expedient to include both lease and non-lease components as a single component and account for it as a lease for all asset classes. The Company also elected to apply the short-term lease exception for all leases. Under the short-term lease exception, the Company will not recognize ROU assets or lease liabilities for leases that, at the acquisition date, have a remaining lease term of 12 months or less. The ASU had a material impact to the Company’s condensed consolidated balance sheet, but did not have an impact on its condensed consolidated statement of income. The most significant impact was the recognition of ROU assets and lease liabilities for its operating leases. |
Basis of Presentation (Tables)
Basis of Presentation (Tables) | 3 Months Ended |
Mar. 29, 2019 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Common Stock Dividends Declared Per Share | The Company declared and paid cash dividends per common share during the periods presented as follows: Fiscal Year 2019 Dividends Amount Per Share (in thousands) First Quarter $ 0.16 $ 8,240 Total $ 0.16 $ 8,240 Fiscal Year 2018 Dividends Amount Per Share (in thousands) First Quarter $ 0.13 $ 6,700 Second Quarter 0.13 6,764 Third Quarter 0.13 6,765 Fourth Quarter 0.13 6,723 Total $ 0.52 $ 26,952 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 3 Months Ended |
Mar. 29, 2019 | |
Fair Value Disclosures [Abstract] | |
Assets and Liabilities Measured at Fair Value on Recurring Basis | The fair value of these certain financial assets and liabilities was determined using the following inputs at March 29, 2019: Fair Value Measurements at Reporting Date Using (In thousands) Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Money market securities (1) $ 770 $ 770 $ - $ - Fixed income available-for-sale securities (2) 92,680 - 92,680 - Fixed income trading securities held in deferred compensation plan (3) 25,504 25,504 - - Equity trading securities held in deferred compensation plan (3) 46,240 46,240 - - Total $ 165,194 $ 72,514 $ 92,680 $ - Liabilities Deferred compensation plan (4) 73,119 73,119 - - Total $ 73,119 $ 73,119 $ - $ - (1) Included in cash and cash equivalents on the Company’s unaudited condensed consolidated balance sheet. (2) Included in short-term investments on the Company’s unaudited condensed consolidated balance sheet. (3) Included in prepaid expenses and other current assets and deferred compensation plan assets on the Company’s unaudited condensed consolidated balance sheet. (4) Included in accrued payroll and employee benefits and deferred compensation plan liabilities on the Company’s unaudited condensed consolidated balance sheet. The fair value of these certain financial assets and liabilities was determined using the following inputs at December 28, 2018: Fair Value Measurements at Reporting Date Using Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Money market securities (1) $ 6,213 $ 6,213 $ - $ - Fixed income available for sale securities (2) 81,495 - 81,495 - Fixed income trading securities held in deferred compensation plan (3) 18,618 18,618 - - Equity trading securities held in deferred compensation plan (3) 39,160 39,160 - - Total $ 145,486 $ 63,991 $ 81,495 $ - Liabilities Deferred compensation plan (4) 59,349 59,349 - - Total $ 59,349 $ 59,349 $ - $ - (1) Included in cash and cash equivalents on the Company’s unaudited condensed consolidated balance sheet. (2) Included in short-term investments on the Company’s unaudited condensed consolidated balance sheet. (3) (4) Included in accrued payroll and employee benefits and deferred compensation plan liabilities on the Company’s unaudited condensed consolidated balance sheet. |
Cash, cash equivalents and short-term investments | Cash, cash equivalents and short-term investments consisted of the following as of March 29, 2019: Gross Gross Amortized Unrealized Unrealized Estimated (In thousands) Cost Gains Losses Fair Value Classified as current assets: Cash $ 73,310 $ - $ - $ 73,310 Cash equivalents: Money market securities 770 - - 770 U.S. Treasury securities 5,000 - - 5,000 Total cash equivalents 5,770 - - 5,770 Total cash and cash equivalents 79,080 - - 79,080 Short-term investments: U.S. Treasury and agency securities 92,613 174 (107 ) 92,680 Total short-term investments 92,613 174 (107 ) 92,680 Total cash, cash equivalents and short-term investments $ 171,693 $ 174 $ (107 ) $ 171,760 Cash, cash equivalents and short-term investments consisted of the following as of December 28, 2018: Amortized Unrealized Unrealized Estimated (In thousands) Cost Gains Losses Fair Value Classified as current assets: Cash $ 120,846 $ - $ - $ 120,846 Cash equivalents: Money market securities 6,213 - - 6,213 Total cash equivalents 6,213 - - 6,213 Total cash and cash equivalents 127,059 - - 127,059 Short-term investments: U.S. Treasury and agency securities 81,634 91 (230 ) 81,495 Total short-term investments 81,634 91 (230 ) 81,495 Total cash, cash equivalents and short-term investments $ 208,693 $ 91 $ (230 ) $ 208,554 |
Summary of Cost and Estimated Fair Value of Short Term Fixed Income Securities | The following table summarizes the cost and estimated fair value of short-term fixed income securities classified as short-term investments based on stated effective maturities as of March 29, 2019: Amortized Estimated (In thousands) Cost Fair Value Due within one year $ 46,919 $ 46,815 Due between one and two years 45,694 45,865 Total $ 92,613 $ 92,680 |
Net Income Per Share (Tables)
Net Income Per Share (Tables) | 3 Months Ended |
Mar. 29, 2019 | |
Earnings Per Share [Abstract] | |
Reconciles Shares to Calculate Basic and Diluted Net Income Per Share | The following schedule reconciles the shares used to calculate basic and diluted net income per share: Three Months Ended (In thousands) March 29, 2019 March 30, 2018 Shares used in basic per share computation 52,536 52,744 Effect of dilutive common stock options outstanding 455 322 Effect of dilutive restricted stock units outstanding 823 946 Shares used in diluted per share computation 53,814 54,012 |
Supplemental Cash Flow Inform_2
Supplemental Cash Flow Information (Tables) | 3 Months Ended |
Mar. 29, 2019 | |
Supplemental Cash Flow Information [Abstract] | |
Supplemental Disclosure of Cash Flow Information | The following is supplemental disclosure of cash flow information: Three Months Ended (In thousands) March 29, 2019 March 30, 2018 Cash paid during period: Income taxes $ 440 $ 678 Non-cash investing and financing activities: Unrealized gain (loss) on short-term investments $ 154 $ (40 ) Vested stock unit awards issued to settle accrued bonuses $ 7,947 $ 7,643 Accrual for capital expenditures $ 1,903 $ 299 Right-of-use asset obtained in exchange for operating lease obligations $ 25,653 $ - |
Accounts Receivable, Net (Table
Accounts Receivable, Net (Tables) | 3 Months Ended |
Mar. 29, 2019 | |
Receivables [Abstract] | |
Accounts Receivable, Net | At March 29, 2019 and December 28, 2018, accounts receivable, net, was comprised of the following: March 29, December 28, (In thousands) 2019 2018 Billed accounts receivable $ 78,814 $ 73,905 Unbilled accounts receivable 44,763 35,975 Allowance for contract losses and doubtful accounts (4,713 ) (4,066 ) Total accounts receivable, net $ 118,864 $ 105,814 |
Segment Reporting (Tables)
Segment Reporting (Tables) | 3 Months Ended |
Mar. 29, 2019 | |
Segment Reporting [Abstract] | |
Segment Reporting Information, by Segment | Segment information for the three months ended March 29, 2019 and March 30, 2018 follows: Revenues Three Months Ended (In thousands) March 29, 2019 March 30, 2018 Engineering and Other Scientific $ 80,254 $ 77,047 Environmental and Health 18,777 19,410 Total revenues $ 99,031 $ 96,457 Operating Income Three Months Ended (In thousands) March 29, 2019 March 30, 2018 Engineering and Other Scientific $ 25,974 $ 25,913 Environmental and Health 6,196 6,624 Total segment operating income 32,170 32,537 Corporate operating expense (16,416 ) (10,939 ) Total operating income $ 15,754 $ 21,598 Capital Expenditures Three Months Ended (In thousands) March 29, 2019 March 30, 2018 Engineering and Other Scientific $ 1,778 $ 813 Environmental and Health 43 51 Total segment capital expenditures 1,821 864 Corporate capital expenditures 4,520 5,946 Total capital expenditures $ 6,341 $ 6,810 Depreciation and Amortization Three Months Ended (In thousands) March 29, 2019 March 30, 2018 Engineering and Other Scientific $ 1,121 $ 1,095 Environmental and Health 45 39 Total segment depreciation and amortization 1,166 1,134 Corporate depreciation and amortization 424 421 Total depreciation and amortization $ 1,590 $ 1,555 |
Leases (Tables)
Leases (Tables) | 3 Months Ended |
Mar. 29, 2019 | |
Leases [Abstract] | |
Lease, Cost | (In thousands) Three Months Ended March 29, 2019 Operating lease cost $ 1,870 Variable lease cost $ 380 Short-term lease cost $ 95 |
Supplemental Cash Flow Information Related to Lease | Supplemental cash flow information related to operating leases was as follows: (In thousands) Three Months Ended March 29, 2019 Cash paid for amounts included in the measurement of lease liabilities: $ 2,534 |
Supplemental Balance Sheet Information Related to Lease | Supplemental balance sheet information related to operating leases was as follows: Three Months Ended March 29, 2019 Weighted Average Remaining Lease Term 5.6 years Weighted Average Discount Rate 4.5 % |
Maturities of Lease Liabilities | Maturities of operating lease liabilities as of March 29, 2019: Operating (In thousands) Leases 2019 (excluding three months ended March 29, 2019) $ 4,700 2020 6,001 2021 4,950 2022 3,894 2023 2,601 2024 1,693 2025 1,491 2026 1,507 2027 1,466 Total lease payments $ 28,303 Less imputed interest (3,982 ) Total lease liability $ 24,321 |
Basis of Presentation - Additio
Basis of Presentation - Additional Information (Detail) - $ / shares | 1 Months Ended | |||
Apr. 18, 2019 | Mar. 29, 2019 | Dec. 28, 2018 | May 31, 2018 | |
Class of Stock [Line Items] | ||||
Common Stock, Shares Authorized | 120,000,000 | 120,000,000 | 120,000,000 | |
Subsequent Event | ||||
Class of Stock [Line Items] | ||||
Common stock, dividends per share declared, subsequent event | $ 0.16 | |||
Dividends Payable, Date Declared | Apr. 18, 2019 | |||
Dividends Payable, Date to be Paid | Jun. 21, 2019 | |||
Dividends Payable, Date of Record | Jun. 7, 2019 |
Common Stock Dividends Declared
Common Stock Dividends Declared And Paid Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | ||||
Mar. 29, 2019 | Dec. 28, 2018 | Sep. 28, 2018 | Jun. 29, 2018 | Mar. 30, 2018 | Dec. 28, 2018 | |
Class of Stock [Line Items] | ||||||
Dividends Per Share | $ 0.16 | $ 0.13 | $ 0.13 | $ 0.13 | $ 0.13 | $ 0.52 |
Amount | $ 8,240 | $ 6,723 | $ 6,765 | $ 6,764 | $ 6,700 | $ 26,952 |
Revenue Recognition- Additional
Revenue Recognition- Additional Information (Detail) - USD ($) | 3 Months Ended | |
Mar. 29, 2019 | Mar. 30, 2018 | |
Revenues | $ 99,031,000 | $ 96,457,000 |
Deferred Revenue, Revenue Recognized | 3,411,000 | |
Subcontractor Fees Not Included In Revenues | 4,200,000 | 10,200,000 |
Engineering and Other Scientific [Member] | Time And Materials Contracts [Member] | ||
Revenues | 65,379,000 | 64,557,000 |
Engineering and Other Scientific [Member] | Fixed Price Contracts [Member] | ||
Revenues | 14,875,000 | 12,446,000 |
Environmental and Health [Member] | Time And Materials Contracts [Member] | ||
Revenues | 18,018,000 | 18,614,000 |
Environmental and Health [Member] | Fixed Price Contracts [Member] | ||
Revenues | 759,000 | 840,000 |
Sales Revenue, Net [Member] | Time And Materials Contracts [Member] | ||
Revenues | $ 83,397,000 | $ 83,171,000 |
Concentration Risk, Percentage | 84.00% | 86.00% |
Sales Revenue, Net [Member] | Fixed Price Contracts [Member] | ||
Revenues | $ 15,634,000 | $ 13,286,000 |
Concentration Risk, Percentage | 16.00% | 14.00% |
Assets and Liabilities Measured
Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands | Mar. 29, 2019 | Dec. 28, 2018 | |
Assets | |||
Money market securities | [1] | $ 770 | $ 6,213 |
Total | 165,194 | 145,486 | |
Liabilities | |||
Deferred compensation plan | [2] | 73,119 | 59,349 |
Total | 73,119 | 59,349 | |
Fixed income securities | |||
Assets | |||
Fixed income available-for-sale securities | [3] | 92,680 | 81,495 |
Fixed income trading securities held in deferred compensation plan | [4] | 25,504 | 18,618 |
Equity securities | |||
Assets | |||
Equity trading securities held in deferred compensation plan | [4] | 46,240 | 39,160 |
Fair Value, Inputs, Level 1 | |||
Assets | |||
Money market securities | [1] | 770 | 6,213 |
Total | 72,514 | 63,991 | |
Liabilities | |||
Deferred compensation plan | [2] | 73,119 | 59,349 |
Total | 73,119 | 59,349 | |
Fair Value, Inputs, Level 1 | Fixed income securities | |||
Assets | |||
Fixed income available-for-sale securities | [3] | 0 | 0 |
Fixed income trading securities held in deferred compensation plan | [4] | 25,504 | 18,618 |
Fair Value, Inputs, Level 1 | Equity securities | |||
Assets | |||
Equity trading securities held in deferred compensation plan | [4] | 46,240 | 39,160 |
Fair Value, Inputs, Level 2 | |||
Assets | |||
Money market securities | [1] | 0 | 0 |
Total | 92,680 | 81,495 | |
Liabilities | |||
Deferred compensation plan | [2] | 0 | 0 |
Total | 0 | 0 | |
Fair Value, Inputs, Level 2 | Fixed income securities | |||
Assets | |||
Fixed income available-for-sale securities | [3] | 92,680 | 81,495 |
Fixed income trading securities held in deferred compensation plan | [4] | 0 | 0 |
Fair Value, Inputs, Level 2 | Equity securities | |||
Assets | |||
Equity trading securities held in deferred compensation plan | [4] | 0 | 0 |
Fair Value, Inputs, Level 3 | |||
Assets | |||
Money market securities | [1] | 0 | 0 |
Total | 0 | 0 | |
Liabilities | |||
Deferred compensation plan | [2] | 0 | 0 |
Total | 0 | 0 | |
Fair Value, Inputs, Level 3 | Fixed income securities | |||
Assets | |||
Fixed income available-for-sale securities | [3] | 0 | 0 |
Fixed income trading securities held in deferred compensation plan | [4] | 0 | 0 |
Fair Value, Inputs, Level 3 | Equity securities | |||
Assets | |||
Equity trading securities held in deferred compensation plan | [4] | $ 0 | $ 0 |
[1] | Included in cash and cash equivalents on the Company’s unaudited condensed consolidated balance sheet. | ||
[2] | Included in accrued payroll and employee benefits and deferred compensation plan liabilities on the Company’s unaudited condensed consolidated balance sheet. | ||
[3] | Included in short-term investments on the Company’s unaudited condensed consolidated balance sheet. | ||
[4] | Included in prepaid expenses and other current assets and deferred compensation plan assets on the Company’s unaudited condensed consolidated balance sheet. |
Cash, cash equivalents and shor
Cash, cash equivalents and short-term investments (Detail) - USD ($) $ in Thousands | Mar. 29, 2019 | Dec. 29, 2017 |
Fair Value Measurements [Line Items] | ||
Amortized Cost | $ 171,693 | $ 208,693 |
Gross Unrealized Gains | 174 | 91 |
Gross Unrealized Losses | (107) | (230) |
Estimated Fair Value | 171,760 | 208,554 |
U.S. Treasury and agency securities | ||
Fair Value Measurements [Line Items] | ||
Amortized Cost | 92,613 | 81,634 |
Gross Unrealized Gains | 174 | 91 |
Gross Unrealized Losses | (107) | (230) |
Estimated Fair Value | 92,680 | 81,495 |
Cash | ||
Fair Value Measurements [Line Items] | ||
Amortized Cost | 73,310 | 120,846 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | 0 | 0 |
Estimated Fair Value | 73,310 | 120,846 |
Money market securities | ||
Fair Value Measurements [Line Items] | ||
Amortized Cost | 770 | 6,213 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | 0 | 0 |
Estimated Fair Value | 770 | 6,213 |
U.S. Treasury securities | ||
Fair Value Measurements [Line Items] | ||
Amortized Cost | 5,000 | |
Gross Unrealized Gains | 0 | |
Gross Unrealized Losses | 0 | |
Estimated Fair Value | 5,000 | |
Total cash equivalents | ||
Fair Value Measurements [Line Items] | ||
Amortized Cost | 5,770 | 6,213 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | 0 | 0 |
Estimated Fair Value | 5,770 | 6,213 |
Total cash and cash equivalents | ||
Fair Value Measurements [Line Items] | ||
Amortized Cost | 79,080 | 127,059 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | 0 | 0 |
Estimated Fair Value | 79,080 | 127,059 |
Total short-term investments | ||
Fair Value Measurements [Line Items] | ||
Amortized Cost | 92,613 | 81,634 |
Gross Unrealized Gains | 174 | 91 |
Gross Unrealized Losses | (107) | (230) |
Estimated Fair Value | $ 92,680 | $ 81,495 |
Summarizes Cost And Estimated F
Summarizes Cost And Estimated Fair Value Of Short Term Fixed Income Securities (Detail) - USD ($) $ in Thousands | Mar. 29, 2019 | Dec. 28, 2018 |
Fair Value Measurements [Line Items] | ||
Due within one year, Amortized Cost | $ 46,919 | |
Due between one and two years, Amortized Cost | 45,694 | |
Total Amortized Cost | 92,613 | |
Due within one year, Estimated Fair Value | 46,815 | |
Due between one and two years, Estimated Fair Value | 45,865 | |
Total Estimated Fair Value | $ 92,680 | $ 81,495 |
Net Income Per Share - Addition
Net Income Per Share - Additional Information (Detail) | 3 Months Ended |
Mar. 29, 2019$ / sharesshares | |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares | 24,176 |
Weighted Average Exercise Price For Antidilutive Shares | $ / shares | $ 54.95 |
Reconciles the Denominators of
Reconciles the Denominators of the Company's Calculation for Basic and Diluted Net Income per Share (Detail) - shares shares in Thousands | 3 Months Ended | |
Mar. 29, 2019 | Mar. 30, 2018 | |
Schedule Of Earnings Per Share Basic and Diluted [Line Items] | ||
Shares used in basic per share computation | 52,536 | 52,744 |
Shares used in diluted per share computation | 53,814 | 54,012 |
Employee Stock Option | ||
Schedule Of Earnings Per Share Basic and Diluted [Line Items] | ||
Effect of dilutive stock outstanding | 455 | 322 |
Restricted Stock Units (RSUs) | ||
Schedule Of Earnings Per Share Basic and Diluted [Line Items] | ||
Effect of dilutive stock outstanding | 823 | 946 |
Stock-Based Compensation - Addi
Stock-Based Compensation - Additional Information (Detail) - USD ($) | 3 Months Ended | |
Mar. 29, 2019 | Mar. 30, 2018 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Share Based Compensation Arrangement By Share Based Payment Award Options Expiration Term | 10 years | |
Employee Stock Option | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Stock based compensation expense | $ 133,000 | $ 549,000 |
Vesting percentage of stock options granted per year | 25.00% | |
Stock based compensation, vesting period | 4 years | |
Vested Restricted Stock Awards | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Stock based compensation expense | $ 2,068,000 | 2,232,000 |
Stock based compensation, holding period | 4 years | |
Vested Restricted Stock Awards | Maximum | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Percentage of annual bonus settled with fully vested restricted stock unit awards | 40.00% | |
Unvested Restricted Stock Awards | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Stock based compensation expense | $ 3,530,000 | $ 3,508,000 |
Unvested Restricted Stock Awards | Minimum | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Recipient age to expense award on grant date | 59 years 6 months | |
Unvested Stock Options [Member] | Minimum | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Recipient age to expense award on grant date | 59 years 6 months | |
Unvested Restricted Stock [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Stock based compensation, vesting period | 4 years |
Treasury Stock - Additional Inf
Treasury Stock - Additional Information (Detail) - USD ($) | Mar. 29, 2019 | Jan. 31, 2019 | Oct. 19, 2016 |
Equity, Class of Treasury Stock [Line Items] | |||
Stock Repurchase Program, Authorized Amount | $ 75,000,000 | $ 35,000,000 | |
Remaining authorized amount for repurchase of common stock | $ 92,462,000 |
Deferred Compensation Plans - A
Deferred Compensation Plans - Additional Information (Detail) - USD ($) | 3 Months Ended | ||
Mar. 29, 2019 | Mar. 30, 2018 | Dec. 28, 2018 | |
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items] | |||
Trading securities | $ 71,744,000 | $ 57,778,000 | |
Deferred compensation plan vested amounts due | 73,119,000 | $ 59,349,000 | |
Change in market value of trust assets | $ 5,869,000 | $ (305,000) | |
Maximum | |||
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items] | |||
Percentage of compensation deferred | 100.00% |
Supplemental Cash Flow Inform_3
Supplemental Cash Flow Information (Detail) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 29, 2019 | Mar. 30, 2018 | |
Cash paid during period: | ||
Income taxes | $ 440 | $ 678 |
Non-cash investing and financing activities: | ||
Unrealized (loss) gain on short-term investments | 154 | (40) |
Vested stock unit awards issued to settle accrued bonuses | 7,947 | 7,643 |
Accrual for capital expenditures | 1,903 | 299 |
Right-of-use asset obtained in exchange for operating lease obligations | $ 25,653 | $ 0 |
Accounts Receivable, Net - Addi
Accounts Receivable, Net - Additional Information (Detail) - USD ($) $ in Thousands | Mar. 29, 2019 | Jan. 29, 2019 | Dec. 28, 2018 |
Accounts, Notes, Loans and Financing Receivable [Line Items] | |||
Accounts Receivable, Net, Current | $ 118,864 | $ 6,000 | $ 105,814 |
Accounts Receivable, Net (Detai
Accounts Receivable, Net (Detail) - USD ($) $ in Thousands | Mar. 29, 2019 | Jan. 29, 2019 | Dec. 28, 2018 |
Accounts, Notes, Loans and Financing Receivable [Line Items] | |||
Allowance for contract losses and doubtful accounts | $ (4,713) | $ (4,066) | |
Total accounts receivable, net | 118,864 | $ 6,000 | 105,814 |
Billed accounts receivable | |||
Accounts, Notes, Loans and Financing Receivable [Line Items] | |||
Accounts Receivable | 78,814 | 73,905 | |
Unbilled accounts receivable | |||
Accounts, Notes, Loans and Financing Receivable [Line Items] | |||
Accounts Receivable | $ 44,763 | $ 35,975 |
Segment Reporting - Additional
Segment Reporting - Additional Information (Detail) | 3 Months Ended | 12 Months Ended | |
Mar. 29, 2019 | Mar. 30, 2018 | Dec. 28, 2018 | |
Segment Reporting Information [Line Items] | |||
Percentage of Company's revenue | 10.00% | ||
Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | |||
Segment Reporting Information [Line Items] | |||
Concentration Risk, Percentage | 16.00% | 12.00% | |
Accounts Receivable [Member] | Customer Concentration Risk [Member] | |||
Segment Reporting Information [Line Items] | |||
Percentage of account receivable | 13.00% | 21.00% |
Segment Information (Detail)
Segment Information (Detail) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 29, 2019 | Mar. 30, 2018 | |
Segment Reporting Information [Line Items] | ||
Revenues | $ 99,031 | $ 96,457 |
Operating Income | 15,754 | 21,598 |
Capital Expenditures | 6,341 | 6,810 |
Depreciation and Amortization | 1,590 | 1,555 |
Operating segments | ||
Segment Reporting Information [Line Items] | ||
Operating Income | 32,170 | 32,537 |
Capital Expenditures | 1,821 | 864 |
Depreciation and Amortization | 1,166 | 1,134 |
Engineering and Other Scientific | ||
Segment Reporting Information [Line Items] | ||
Revenues | 80,254 | 77,047 |
Operating Income | 25,974 | 25,913 |
Capital Expenditures | 1,778 | 813 |
Depreciation and Amortization | 1,121 | 1,095 |
Environmental and Health | ||
Segment Reporting Information [Line Items] | ||
Revenues | 18,777 | 19,410 |
Operating Income | 6,196 | 6,624 |
Capital Expenditures | 43 | 51 |
Depreciation and Amortization | 45 | 39 |
Corporate | ||
Segment Reporting Information [Line Items] | ||
Operating Income | (16,416) | (10,939) |
Capital Expenditures | 4,520 | 5,946 |
Depreciation and Amortization | $ 424 | $ 421 |
Leases - Additional Information
Leases - Additional Information (Details) | 3 Months Ended |
Mar. 29, 2019USD ($) | |
Phoenix Arizona [Member] | |
Lessee, Operating Lease, Term of Contract | 30 years |
Other Income [Member] | |
Rental Income | $ 741,000 |
Components of Lease Expense (De
Components of Lease Expense (Details) - Other Operating Income (Expense) [Member] $ in Thousands | 3 Months Ended |
Mar. 29, 2019USD ($) | |
Operating lease cost | $ 1,870 |
Variable lease cost | 380 |
Short-term lease cost | $ 95 |
Supplemental Cash Flow Inform_4
Supplemental Cash Flow Information (Details) $ in Thousands | 3 Months Ended |
Mar. 29, 2019USD ($) | |
Cash paid for amounts included in the measurement of lease liabilities: | |
Operating cash flows from operating leases | $ 2,534 |
Supplemental Balance Sheet Info
Supplemental Balance Sheet Information (Details) | Mar. 29, 2019 |
Weighted Average Remaining Lease Term | 5 years 7 months 6 days |
Weighted Average Discount Rate | 4.50% |
Maturities of Lease Liabilities
Maturities of Lease Liabilities (Details) $ in Thousands | Mar. 29, 2019USD ($) |
2019 (excluding three months ended March 29, 2019) | $ 4,700 |
2020 | 6,001 |
2021 | 4,950 |
2022 | 3,894 |
2023 | 2,601 |
2024 | 1,693 |
2025 | 1,491 |
2026 | 1,507 |
2027 | 1,466 |
Total lease payments | 28,303 |
Less imputed interest | (3,982) |
Total lease liability | $ 24,321 |